Author:
Eleazu Chinedum Ogbonnaya,Eleazu Kate Chinedum,Chukwuma Sonia,Essien Udeme Nelson
Abstract
AbstractStreptozotocin (STZ) (2-deoxy-2-({[methyl(nitroso)amino]carbonyl}amino)-β-D-glucopyranose) is a naturally occurring diabetogenic compound, produced by the soil bacterium streptomyces achromogenes, that exhibits broad spectrum of antibacterial properties. Streptozotocin functions as a DNA synthesis inhibitor in both bacterial and mammalian cells. In mammalian cells, the actual mechanism and metabolic targets of STZ toxicity that results in cell death is not known. This review identifies four key areas that explain the mechanism of the cytotoxicity of STZ in mammalian cell lines, investigates the practical aspects of using STZ in experimental animals and the potential risks of its exposure to human health.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference64 articles.
1. Dolan ME: Inhibition of DNA repair as a means of increasing the antitumor activity of DNA active agents. Adv Drug Del Rev 1997, 26: 105–118. 10.1016/S0169-409X(97)00028-8
2. Vivek KS: Streptozotocin: an experimental tool in diabetes and alzheimer’s disease (A- Review). Int J Pharma Res Dev 2010,2(1):1–7.
3. Lenzen S: Alloxan and streptozotocin diabetes. Diabetologia 2007, 51: 216–226.
4. Rakieten L, Rakieten ML, Nadkarni MV: Studies on the diabetogenic action of Streptozotocin (NSC-37917). Cancer Chem Rep 1963, 29: 91–98.
5. Rerup CC: Drugs producing diabetes through damage of the insulin secreting cells. Pharmacol Rev 1970, 22: 485–518.
Cited by
271 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献